EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing

Fred C Christians, Jamilla Akhund-Zade, Kristin Jarman, Shivkumar Venkatasubrahmanyam, Nicholas Noll, Timothy A Blauwkamp, Sivan Bercovici, Aga Zielinska, Amy L Carr, Arryn Craney iD, Matthew Pike, John Joseph Farrell und 5 weitere

Journal of Clinical Microbiology · 2024

DOI: 10.1128/jcm.00425-24 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Clinical Microbiology, 2024. Verfasst von Fred C Christians und 16 weiteren Autor:innen. Beteiligte Einrichtung: Karius, Redwood City, California, USA. Hauptthemen laut MEDLINE: Drug Resistance, Bacterial, Bacteria. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karius.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sequencing of plasma microbial cell-free DNA (mcfDNA) has gained increased acceptance as a valuable adjunct to standard-of-care testing for diagnosis of infections throughout the body. Here, we report the analytical and clinical validation of a novel application of mcfDNA sequencing, the non-invasive detection of seven common antimicrobial resistance (AMR) genetic markers in 18 important pathogens. The AMR markers include SCC mec , mecA, mecC , vanA, vanB , bla CTX-M , and bla KPC . The AMR markers were computationally linked to the pathogens detected. Analytical validation showed high reproducibility (100%), inclusivity (54 to 100%), and exclusivity (100%). Clinical accuracy was assessed with 114 unique plasma samples from patients at seven study sites with concordant culture results for target bacteria from a variety of specimen types and correlated with available phenotypic antimicrobial susceptibility test results and genotypic results. The positive percent agreement (PPA), negative percent agreement (NPA), and diagnostic yield (DY) were estimated for each AMR marker. DY was defined as the percentage of tests that yielded an actionable result of either detected or not detected. The results for the combination of SCC mec and mecA for staphylococci were PPA 19/20 (95.0%), NPA 21/22 (95.4%), DY 42/60 (70.0%); vanA for enterococci were PPA 3/3 (100%), NPA 2/2 (100%), DY 5/6 (83.3%); bla CTX-M for gram-negative bacilli were PPA 5/6 (83.3%), NPA 29/29 (100%), DY 35/49 (71.4%); and bla KPC for gram-negative bacilli were PPA 0/2 (0%), NPA: 23/23 (100%), DY 25/44 (56.8%). The addition of AMR capability to plasma mcfDNA sequencing should provide clinicians with an effective new culture-independent tool for optimization of therapy. IMPORTANCE This manuscript is ideally suited for the Innovative Diagnostic Methods sections as it reports the analytical and clinical validation of a novel application of plasma microbial cell-free DNA sequencing for direct detection of seven selected antimicrobial resistance markers in 18 target pathogens. Clearly, it has potential clinical utility in optimizing therapy and was incorporated into the Karius test workflow in September 2023. In addition, the workflow could readily be adapted to expand the number of target bacteria and antimicrobial resistance markers as needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, BacterialBacteriaHumansReproducibility of ResultsCell-Free Nucleic AcidsBacterial InfectionsMicrobial Sensitivity TestsSequence Analysis, DNAGenetic MarkersDNA, BacterialMolecular Diagnostic TechniquesAnti-Bacterial AgentsFemaleMale

Stichwörter der Autor:innen

antimicrobial resistance genesmetagenomicsmicrobial cell-free DNA

Substanzen

Cell-Free Nucleic AcidsGenetic MarkersDNA, BacterialAnti-Bacterial Agents

Autor:innen und Institutionen

  • Karius, Redwood City, California, USA.
  • AdventHealth Orlando, Orlando, Florida, USA.
  • Orlando Health, Orlando, Florida, USA.
  • Carle Foundation Hospital, Urbana, Illinois, USA.
  • OSF Healthcare, Peoria, Illinois, USA.
  • City of Hope National Medical Center, Duarte, California, USA.

ORCID-Profile: Arryn Craney, Frederick S Nolte

Förderung

  • Karius

Zitieren

APA

Christians, F. C., Akhund-Zade, J., Jarman, K., Venkatasubrahmanyam, S., Noll, N., Blauwkamp, T. A., Bercovici, S., Zielinska, A., Carr, A. L., Craney, A., Pike, M., Farrell, J. J., Dadwal, S., Wood, J. B., Matkovich, E., McAdams, S., & Nolte, F. S. (2024). Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00425-24

Vancouver

Christians FC, Akhund-Zade J, Jarman K, Venkatasubrahmanyam S, Noll N, Blauwkamp TA, et al. Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing. Journal of Clinical Microbiology. 2024. doi:10.1128/jcm.00425-24

BibTeX
@article{Christians2024,
  author = {Christians, Fred C and Akhund-Zade, Jamilla and Jarman, Kristin and Venkatasubrahmanyam, Shivkumar and Noll, Nicholas and Blauwkamp, Timothy A and Bercovici, Sivan and Zielinska, Aga and Carr, Amy L and Craney, Arryn and Pike, Matthew and Farrell, John Joseph and Dadwal, Sanjeet and Wood, James B and Matkovich, Efrat and McAdams, Staci and Nolte, Frederick S},
  title = {Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing},
  journal = {Journal of Clinical Microbiology},
  year = {2024},
  doi = {10.1128/jcm.00425-24}
}
Kostenlos starten →